2012
A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy
Shen K, Song N, Kim Y, Tian C, Rice SD, Gabrin MJ, Symmans WF, Pusztai L, Lee JK. A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy. PLOS ONE 2012, 7: e49529. PMID: 23185353, PMCID: PMC3504014, DOI: 10.1371/journal.pone.0049529.Peer-Reviewed Original ResearchConceptsMulti-gene predictorsPatients' clinical outcomesClinical outcomesCancer patientsTherapeutic responseStandard combination chemotherapyBreast cancer patientsClinical outcome measurementsPatient's therapeutic responseBreast cancer cell linesCancer cell linesNegative patientsCombination chemotherapyPatient cohortPathological responseBreast cancerEstrogen receptorClinical utilityOutcome measurementsChemotherapyPatientsCell linesOutcomesPredictorsCOXEN
2007
Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer
Pusztai L, Anderson K, Hess KR. Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer. Clinical Cancer Research 2007, 13: 6080-6086. PMID: 17947471, DOI: 10.1158/1078-0432.ccr-07-0809.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase II as TopicGene Expression ProfilingGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceOligonucleotide Array Sequence AnalysisPharmacogeneticsProbabilityRNA, MessengerTissue DistributionTrastuzumabConceptsPhase II studyPhase II trialII trialII studyBreast cancerTwo-stage phase II trialPhase II clinical trialPhase II trial designPredictors of responseMarker-positive patientsPhase II designUnselected patientsPatient populationClinical trialsTrastuzumab responseInsufficient responseTrial designResponse markersSame drugResponse rateMarker testingPotential predictorsMarker assessmentTrialsPatientsLimitations of pharmacogenomic predictor discovery in Phase II clinical trials
Pusztai L. Limitations of pharmacogenomic predictor discovery in Phase II clinical trials. Pharmacogenomics 2007, 8: 1443-1448. PMID: 17979517, DOI: 10.2217/14622416.8.10.1443.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials, Phase II as TopicDrug TherapyGenetic MarkersHumansPharmacogeneticsReproducibility of ResultsGene-expression microarrays provide new prognostic and predictive tests for breast cancer
Gong Y, Symmans WF, Pusztai L. Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. Pharmacogenomics 2007, 8: 1359-1368. PMID: 17979510, DOI: 10.2217/14622416.8.10.1359.Peer-Reviewed Original ResearchConceptsBreast cancerSystemic therapySpecific systemic therapySystemic therapy agentsGene expression microarraysBreast cancer researchProbability of responseTherapeutic regimensClinicopathologic variablesNecessary therapyDisease outcomeIndividual patientsAccurate markerClinical decisionIndividual tumorsCancerPredictive indicatorTherapyPredictive testIndividual basisPatientsCancer researchTherapy agentsMolecular differencesRecent progressionThirty-Gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer
Peintinger F, Anderson K, Mazouni C, Kuerer HM, Hatzis C, Lin F, Hortobagyi GN, Symmans WF, Pusztai L. Thirty-Gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer. Clinical Cancer Research 2007, 13: 4078-4082. PMID: 17634532, DOI: 10.1158/1078-0432.ccr-06-2600.Peer-Reviewed Original ResearchConceptsResidual cancer burdenRCB 0RCB scoreRCB-IIICancer burdenPharmacogenomic testsRCB-IIPreoperative chemotherapyRCB classBreast cancerChemotherapy-resistant diseaseLymph node featuresPathologic reviewPathologic responseResidual tumorStage IPatientsIII groupChemotherapyI groupGene expression profilingCategorical variablesMean scoreScoresCancer
2006
Do Pharmacogenomic Tests Provide Value to Policy Makers?
Shih YC, Pusztai L. Do Pharmacogenomic Tests Provide Value to Policy Makers? PharmacoEconomics 2006, 24: 1173-1177. PMID: 17129072, DOI: 10.2165/00019053-200624120-00002.Peer-Reviewed Original Research
2005
Pharmacogenomics and Clinical Biomarkers in Drug Discovery and Development
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics and Clinical Biomarkers in Drug Discovery and Development. American Journal Of Clinical Pathology 2005, 124: s29-s41. PMID: 16468416, DOI: 10.1309/xyqafanapync6x59.Peer-Reviewed Original ResearchConceptsHuman genome sequenceGene expression profilesGenome sequenceEpigenetic eventsExpression profilesProteomics researchDrug discoveryRapid evolutionComputational biologyPharmaceutical industryMolecular diagnosticsDiscoveryFurther understandingBiosensorRNABiologyAnticancerSequenceClinical biomarkersAnti-inflammatory drugsDrug efficacyToxicityPrediction of responseDevelopmentContinuous technological advancementsDevelopment of pharmacogenomic markers to select preoperative chemotherapy for breast cancer
Lajos P, Symmans F, Hortobagyi G. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 2005, 12: 73-85. PMID: 15858436, DOI: 10.1007/bf02966817.Peer-Reviewed Original ResearchConceptsBreast cancerJapanese Breast Cancer SocietyTexas M. D. Anderson Cancer CenterM. D. Anderson Cancer CenterD. Anderson Cancer CenterEffective adjuvant chemotherapyBreast Cancer SocietyAnderson Cancer CenterAdjuvant chemotherapyCombination of markersPreoperative chemotherapyNew regimensCancer CenterCurrent therapiesBreast centerCancer SocietySmall exploratory studyIndividualized selectionPharmacogenomic markersChemotherapyCancerMolecular characteristicsMarkersTranscriptional profilingAnnual MeetingGene expression profiling of primary breast cancer
Rouzier R, Wagner P, Morandi P, Pusztai L. Gene expression profiling of primary breast cancer. Current Oncology Reports 2005, 7: 38-44. PMID: 15610685, DOI: 10.1007/s11912-005-0024-y.Peer-Reviewed Original ResearchDevelopment of Pharmacogenomic Markers to Select Preoperative Chemotherapy for Breast Cancer
Pusztai L, Symmans FW, Hortobagyi GN. Development of Pharmacogenomic Markers to Select Preoperative Chemotherapy for Breast Cancer. Breast Cancer 2005, 12: 73-85. DOI: 10.2325/jbcs.12.73.Peer-Reviewed Original ResearchConceptsBreast cancerJapanese Breast Cancer SocietyTexas M. D. Anderson Cancer CenterM. D. Anderson Cancer CenterD. Anderson Cancer CenterEffective adjuvant chemotherapyBreast Cancer SocietyAnderson Cancer CenterAdjuvant chemotherapyCombination of markersPreoperative chemotherapyNew regimensCancer CenterCurrent therapiesBreast centerCancer SocietySmall exploratory studyIndividualized selectionPharmacogenomic markersChemotherapyCancerMolecular characteristicsMarkersTranscriptional profilingAnnual Meeting
2004
Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
Pusztai L, Rouzier R, Wagner P, Symmans WF. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Drug Resistance Updates 2004, 7: 325-331. PMID: 15790543, DOI: 10.1016/j.drup.2004.10.002.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBreast NeoplasmsChemotherapy, AdjuvantFemaleHumansPharmacogeneticsConceptsChemotherapy regimensChemotherapy treatmentPatient outcomesBreast cancerClinical utilitySmall exploratory studyIndividualized selectionClinical pharmacogenomicsPredictive testUseful predictorCancerMolecular characteristicsMarker researchTranscriptional profilingRegimensValidation trialsChemotherapyTrialsTargeted Therapies for Cancer 2004
Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted Therapies for Cancer 2004. American Journal Of Clinical Pathology 2004, 122: 598-609. PMID: 15487459, DOI: 10.1309/5cwpu41afr1vym3f.Peer-Reviewed Original ResearchConceptsBcr/abl-positive chronic myelogenous leukemiaNon-small cell lung cancerEmergence of trastuzumabMetastatic colorectal cancerMetastatic breast cancerCell lung cancerRoute of administrationChronic myelogenous leukemiaProteasome inhibitor bortezomibEpidermal growth factor receptor (EGFR) geneNew therapeutic agentsEpidermal growth factor receptorSpecific genetic defectsTargeted anticancer therapiesGrowth factor receptorAgent bevacizumabGrowth factor receptor geneMolecular diagnosticsColorectal cancerCancer patientsLung cancerHematologic malignanciesImatinib mesylateTargeted therapyBreast cancerPerspectives and challenges of clinical pharmacogenomics in cancer
Pusztai L. Perspectives and challenges of clinical pharmacogenomics in cancer. Pharmacogenomics 2004, 5: 451-454. PMID: 15212580, DOI: 10.1517/14622416.5.5.451.Peer-Reviewed Original ResearchPharmacogenomics
Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics. Advances In Anatomic Pathology 2004, 11: 211-220. PMID: 15220824, DOI: 10.1097/01.pap.0000131825.77317.ee.Peer-Reviewed Original ResearchConceptsDisease pathway genesGene expression patternsWhole-genome technologiesHuman genomeTranscriptional profilingGenome technologyPathway genesMolecular basisGenomic microarraysSNP technologySolid Tumors (RECIST) classificationExpression patternsTarget discoveryProteomics researchDrug targetsGenetic variantsNon-genetic factorsAnti-cancer drugsComputational biologyVariety of diseasesField of pharmacogeneticsDrug metabolizing enzymesToxic responseLeukemia/lymphomaGroup of drugsBreast cancer biomarkers and molecular medicine: part II
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine: part II. Expert Review Of Molecular Diagnostics 2004, 4: 169-188. PMID: 14995904, DOI: 10.1586/14737159.4.2.169.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCell Adhesion MoleculesDNADrug Resistance, MultipleEndopeptidasesFemaleGene Expression ProfilingGenes, Tumor SuppressorHumansOncogenesPharmacogeneticsPrognosisProto-Oncogene Proteins c-bcl-2Receptors, EstrogenReceptors, ProgesteroneTelomeraseTranscription FactorsConceptsInvasion-associated proteinsMolecular medicineTumor suppressor geneTranscriptional profilingTranscription factorsDNA repairCell adhesion moleculeDrug resistance proteinsGenomic microarraysApoptosis regulatorSuppressor geneHormone receptor proteinsReceptor proteinBreast cancer biomarkersResistance proteinCancer biomarkersProteinBreast cancer prognostic factorsAdhesion moleculesCancer prognostic factorsPrognostic factorsTherapy responseGenesMethylationTelomerase